Condition
Shigella Infection
Total Trials
5
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (2)
P 2 (2)
Trial Status
Completed4
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04634513Phase 1CompletedPrimary
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
NCT04242264Phase 2Completed
Phase 2 Shigella Vaccine and Challenge
NCT04694235Not ApplicableActive Not Recruiting
Egg Intervention During Pregnancy in Indonesia
NCT01336699Phase 1CompletedPrimary
Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3
NCT00210288Phase 2CompletedPrimary
Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine
Showing all 5 trials